Your SlideShare is downloading. ×
The corporate presentation ennaid therapeutics
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

The corporate presentation ennaid therapeutics

243
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
243
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Curing Infectious Diseases Sept.,2013
  • 2. Our First Target is Dengue Fever 1
  • 3. 400 Million Dengue Infections Annually 2CDC-HeathMap Collaboration, http://www.healthmap.org/dengue/ index.php
  • 4. We Have A Cure For Dengue 3 Control Neutralizing Serum A Control Peptide 57 B Control Peptide ETX-101 C >99% Inhibition
  • 5. ETX-101 Mechanism of Action 4
  • 6. Issued, Filed or Pending Patents 5
  • 7. Dengue Products In Development 6
  • 8. Our Expert Team 7 Robert F. Garry, Ph.D. Inventor – 30 Yrs Chief Science Officer Elizabeth Moore, RPh 30 Yrs Experience Gov’t/Industry Regulatory Affairs Darnisha Harrison Microbiologist/Bus. Dev Licensing – 19yrs President & CEO Scott Michael, Ph.D. Co-inventor – 15 Yrs Scientific Advisor SUPPORT TEAM Adrian Barfied 23 Yrs Pharma Entrepreneur Romeo Ibrahim 20 Yrs Process Scientist Thandeka Myeni, MD 14 Yrs Medical Advisor George Davis 20 Yrs Corporate Affairs TIBA Oncology P4 Healthcare
  • 9. Dengue Therapeutic Development Plan 8 Preclinical Preparation Effectiveness Non-Human Primates Pre-IND Meeting Safety/Toxicity Non-Human Primates IND Submission Phase I/IIa Clinical Trial Phase I/IIa Data Retrieval & Publishing July 2013 Jan 2014 May 2014 Mar 2015 July 2015 May 2016 Oct 2016 $35K $3.7M $265K $3.75M $250K $11M $1M $4,000,000 $4,000,000 $12,000,000
  • 10. Market Potential 9 $63 Per Dose $0 $500 $1,000 $1,500 $2,000 Year 1 Year 2 Year 3 Year 4 Year 5 $1.69 Billion 40% 40% 40% 40% 40% Economic Savings Revenue In Millions
  • 11. Monetization/Exit Strategies 10
  • 12. Dengue Is Just The Beginning 11 West Nile Virus Hepatitis C 30M Annual Infections 170M Annual Infections 200M Additional Doses
  • 13. Thank You I Trust That I Have Thoroughly Convinced You That Ennaid Has The Solution, The Plan & The Team To Develop Cures For All Four Strains Of Dengue Virus, Followed by Hepatitis C Virus & West Nile Virus.